Introduction
Metastatic pancreatic adenocarcinoma is a lethal disease (Evans et al., 1997) . Specifically, its aggressive nature is related to activation of various oncogenes and inactivation of various tumor suppressor genes as well as abnormalities in growth factors and their receptors, which affect the downstream signal transduction pathways involved in the control of growth and differentiation (Korc, 1998; Kern, 2000) . These perturbations confer a tremendous growth advantage to pancreatic cancer cells.
The growth and metastasis of pancreatic adenocarcinoma depend on angiogenesis, which is the formation of new blood vessels from a pre-existing network of capillaries (Folkman, 1997) . Of the numerous angiogenic factors discovered thus far, vascular endothelial growth factor (VEGF) (Senger et al., 1983) , also known as vascular permeability factor (VPF) (Leung et al., 1989) , has been identified as a key mediator of tumor angiogenesis. Physiologically, the pancreas is a highly vascularized organ, and VEGF is quite high in the islets of normal pancreas, whereas it is relatively low in pancreatic ductal epithelial cells (Christofori et al., 1995) . However, there is a significantly elevated expression of VEGF in biopsy specimens of human pancreatic adenocarcinoma (Brown et al., 1993; Itakura et al., 1997) . The mechanism of VEGF expression and its regulation in human pancreatic cancer are mostly unknown. Increasing evidence suggests that VEGF expression is regulated by a plethora of external factors. Major stimulators of VEGF expression include hypoxia and acidosis (Shweiki et al., 1992; Shi et al., 2001a, b) , which occur frequently within diverse types of expanding tumors, particularly in regions surrounding necrotic areas (Shweiki et al., 1992) . The major role of hypoxia in the angiogenesis switch has been clearly demonstrated in a mouse model (Bergers et al., 1999) . However, in many types of tumors, an elevated level of VEGF production can often be detected in tumor cells located in the extreme periphery of the tumor, where there is no apparent hypoxia. These observations are consistent with numerous recent findings indicating that such exogenous factors as hormones, cytokines, and growth factors modulate VEGF expression and then angiogenesis. Also, many tumor cells can constitutively express VEGF in vitro without any apparent external stimulation (Shi et al., 2001a, b) . In fact, loss or inactivation of tumor suppressor genes and activation of oncogenes are associated with VEGF overexpression (Kieser et al., 1994; Vanmeir et al., 1994) . VEGF promoter analyses have revealed several potential transcription factorbinding sites, such as HIF-1, AP-1, AP-2, Egr-1, Sp1 (Tischer et al., 1991) , and many others (Ema et al., 1997; Flamme et al., 1997; Akiri et al., 1998; Stein et al., 1998) , suggesting that multiple signal transduction pathways may be involved in VEGF transcription regulation. A putative binding site for Stat3 has been identified on the VEGF promoter, suggesting its possible role in the regulation of VEGF expression (Niu et al., 2002) .
Stat3, a member of JAK-STAT signaling pathway, is a latent transcription factor, which is activated by phosphorylation (Darnell, 1997) . There are several reports indicating that constitutively activated Stat3 protein is found in various types of tumors including leukemia, breast, head and neck, and prostate (Watson and Mille, 1995; Gouilleux-Gruart et al., 1996; Ni et al., 2000; Grandis et al., 2000) . Activation of Stat3 has been observed in cells transformed in vitro with v-src and abl oncogenes (Danial et al., 1995; Yu et al., 1995) . Cell lines from multiple myelomas that have become growth factor independent require constitutively active Stat3 to protect against apoptosis (Catlett-Falcone et al., 1999) . Thus in many human cancers and transformed cell lines, Stat3 is constitutively activated compared with normal epithelial cells. Furthermore, constitutively activated Stat3 (a mutant produced by substitution of the cysteine residues within the COOH-terminal loop of the SH2 domain of Stat3) induces cellular transformation and tumor formation in nude mice (Bromberg et al., 1999) . These results suggested that Stat3 may function as an oncogene and play a critical role in transformation and tumor progression.
In the present study, we examined whether and how the Stat3 signaling pathway regulates VEGF expression in, and growth and metastasis of, pancreatic cancer. We found that human pancreatic cancer cells have constitutively activated Stat3 and that its activation was directly correlated with the level of VEGF expression. Furthermore, Stat3 directly regulated the promoter of the VEGF gene. Blockade of activated Stat3 by ectopic expression of dominant-negative Stat3 significantly inhibited VEGF expression, and the growth and metastasis of human pancreatic cancer cells. Our results demonstrate that activation of the Stat3 signaling pathway is critical for angiogenesis of pancreatic tumors and suggest that Stat3 signaling pathway is a potential therapeutic target for controlling pancreatic cancer growth and metastasis.
Results

Stat3 expression in human pancreatic cancer tissue
To determine the level of Stat3 expression in human pancreatic cancer tissue cells, whole-cell protein extracts and cellular mRNA were prepared from normal and pancreatic cancer tissue specimens obtained from three patients. Phospho-Stat3 protein expression was determined using Western blot analysis (Figure 1a) , while Stat3 DNA binding activity was determined via electrophoretic mobility shift assay (EMSA) using 20-mg whole-cell extracts and a 32 P-labeled oligonucleotide probe containing a consensus-binding motif for Stat3 (Figure 1b ). In addition, VEGF mRNA expression was Figure 1 Stat3 expression in human pancreatic cancer tissue. Whole-cell protein extracts and cellular mRNA were prepared from normal (N) and pancreatic cancer (T) tissue specimens obtained from three patients. (a) Phospho-Stat3 protein expression was determined using Western blot analysis. (b) Stat3 DNA-binding activity was determined via EMSA using 20-mg whole-cell extracts and a 32 P-labeled oligonucleotide probe containing a consensus-binding motif for Stat3. (c) VEGF mRNA expression was determined using Northern blot analysis. (d) Stat3 DNA binding activity also was determined via EMSA using 5-mg nuclear protein extracts and the same Stat3 oligonucleotide probe. As a control, nuclear protein was extracted from H7 pancreatic adenocarcinoma cells stimulated for 6 h with 100 U/ml of IFN-b. (e) VEGF mRNA expression in these tissues was determined using Northern blot analysis. It should be noted that human pancreatic cancer tissue had a significantly higher level of Stat3 activity than normal tissue did, which directly correlated with VEGF expression Stat 3 and pancreatic cancer angiogenesis D Wei et al determined using Northern blot analysis ( Figure 1c ). To confirm these findings, EMSA also was performed using nuclear protein extract (Figure 1d ). Stat3 activities were directly proportional to the levels of VEGF mRNA expression ( Figure 1e (Figure 2 ).
Constitutive Stat3 expression in human pancreatic cancer cells
We first examined whether Stat3 is activated in pancreatic cancer cells using Western blot analysis with the phospho-Stat3 (tyr-705) antibody ( Figure 3a ) and then using EMSA with a radiolabeled, double-stranded Stat3 consensus-binding motif (Figure 3b ). Eight of the most widely used human pancreatic cancer cell lines (including CaPan-2, HS766T, HPAF-II, MDA Panc-3, BxPc-3, FG, PANC-1, and SW-1990) were tested for activation of Stat3. The Stat3 DNA binding activities were detected at various levels in these cell lines. In addition, the level of VEGF mRNA expression was determined using Northern blot analysis (Figure 3c ). Strong Stat3 DNA-binding activity was observed in BxPc-3, FG, PANC-1, and SW-1990, which had high levels of VEGF expression, while weak Stat3 DNA binding activity was found in CaPan-2, HS766T, HPAF-II, and MDA Panc-3, which had low levels of VEGF expression. The Stat3 DNA binding complex was further confirmed via supershift assay using specific antibodies against Stat3 and Stat1 (Figure 3d ). These results suggest that Stat3 is commonly activated in human pancreatic cancer cells and that Stat3 activation is directly correlated with VEGF expression.
Regulation of the VEGF promoter by Stat3
To assess the effect of Stat3 on VEGF transcription, VEGF promoter-luciferase constructs (Shi et al., 2001a) were cotransfected into HPAF-II cells with increasing concentrations of CA-Stat3 or the control vector lacking Stat3 (pcDNA3). Using the pBA-RL vector as a control to normalize for transfection efficiency, we found that the luciferase activity driven by the VEGF promoter was activated by CA-Stat3. There was not a significant loss of VEGF promoter activation with deletion of the VEGF promoter sequence from À2274 to À1012 bp, whereas further deletion of from À1012 to À789 bp led to substantial loss of VEGF promoter activation by CA-Stat3 (Figure 4a ). These results suggest that the sequence from À1012 to À789 bp was required for VEGF promoter activation by Stat3 in HPAF-II cells in a dose-dependent manner. In addition, there was a putative Stat3-responsive element (SRE) spanning positions from À842 to À849, as was recently reported (Niu et al., 2002) . Site-directed mutagenesis of this SRE was then performed. A base-pair change from TTCC to CGTA of this putative SRE significantly eliminated both promoter transactivation by CA-Stat3 in HPAF-II cells and VEGF promoter inhibition by DN-Stat3 in PANC-1 cells ( Figure 4b ). To provide direct evidence that Stat3 binds to the VEGF promoter, the sequence of the putative Stat3 binding site of the VEGF gene (5'-atccctggacacttcccaaaggac-3') and that of its corresponding mutant (5'-atccctggacaccgtacaaaggac-3') were synthesized; consensus Stat3 sequences (5'-gatccttctgggaattcctagatc-3' and its mutant, 5'-gatccttctgggccgtcctagatc-3'; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as controls. These oligonucleotides were used as probes. EMSA was performed using whole-cell protein lysates prepared from PANC-1 cells. Incubation of protein extracts with these wild-type putative Stat3 probes resulted in the formation of one major shifted DNAprotein complex (indicated as Stat3), but incubation of them with the corresponding Stat3 mutants did not ( Figure 4c ). These experiments indicated that the presence of a functional Stat3 responsive element within the VEGF promoter regulates VEGF expression in human pancreatic cancer cells.
Enforced downregulation of constitutive Stat3 activity
To further determine the effect of altered Stat3 activity on VEGF expression, FG cells were transfected with either CA-Stat3 or DN-Stat3 expression vectors (FLAG-tagged). Whole-cell protein extracts and cellular mRNA were prepared from parental FG, vector control, CA-Stat3-and DN-Stat3-transfected cells. The CA-stat3 and DN-Stat3 protein was probed using an anti-FLAG antibody in Western blot analysis, and altered Stat3 activity was conformed using EMSA (data not shown). Additionally, VEGF promoter activity was determined using the dual luciferase assay system (Figure 5a ), VEGF mRNA expression was determined using Northern blot analysis (Figure 5b ), and VEGF protein secretion was determined using enzyme-linked immunosorbent assay (ELISA) (Figure 5c ). We found that enforced expression of DN-Stat3 significantly suppressed constitutive Stat3 expression, which led to decreased VEGF promoter activity as well as VEGF mRNA and protein expression, whereas transfection of CA-Stat3 further enhanced VEGF expression.
Effects of Stat3 blockade on tumor growth and metastasis
Parental FG cells and FG cells transfected with CAStat3 and DN-Stat3 and a control vector were used to study the kinetics of tumor formation using an ectopic xenograft model. First, tumor cells (1 Â 10 6 cells/mouse) were injected subcutaneously into nude mice in groups of 10. The tumors resulting from injection of DN-Stat3-transfected cells were smaller with much longer latency, whereas CA-Stat3-transfected cells were much more progressive ( Figure 6 ). Furthermore, because ectopic implantation of pancreatic cancer cells rarely leads to distant metastasis in most xenograft models, we used an orthotopic xenograft model to evaluate the effect of Stat3 activation on tumor growth and metastasis. Tumor cells were injected into the tail of the pancreas of mice in groups of 10. The animals were killed 60 days after tumor-cell implantation or when they had become Figure 2 Localization of Stat3 expression in human pancreatic cancer tissue. To localize activated Stat3 in pancreatic cancer cells and determine whether increased constitutive Stat3 activity is associated with increased protein expression, immunohistochemical staining of formalin-fixed, paraffin-embedded tissue specimens using the phospho-Stat3 antibody was performed. It should be noted that there was weak or negative expression of Stat3 in normal tissue specimens obtained from patients not having cancer, whereas there was strong expression of phosphorylated Stat3 in pancreatic adenocarcinoma tissue specimens. The Stat3 staining was mainly localized in the nuclei of tumor epithelial cells. Stat3 overexpression directly correlated with VEGF overexpression and increased vessel density (CD34 staining) Stat 3 and pancreatic cancer angiogenesis D Wei et al moribund. Each tumor was weighed, and the weights in all of the groups of mice were compared. In this study, DN-Stat3-transfected cells produced much smaller tumors and no liver metastases, whereas CA-Stat3-transfected cells produced larger tumors and many more liver metastases (Table 1 ). The altered tumor growth and metastasis was directly correlated with altered VEGF expression and microvessel formation ( Figure 7 ). These results suggested that Constitutive active Stat3 enhances VEGF expression, angiogenesis, tumor growth, and metastasis, whereas Stat3 blockade directly suppressed angiogenesis in pancreatic tumors and hence tumor growth and metastasis.
Discussion
In the present study, we provided evidence that Stat3 regulates VEGF expression and pancreatic tumor angiogenesis, growth, and metastasis. Furthermore, we found constitutive Stat3 activity in both human pancreatic cancer cells and human pancreatic cancer specimens, which was directly correlated with VEGF expression. Blockade of activated Stat3 by ectopic expression of dominant-negative Stat3 in human pancreatic cancer cells significantly suppresses both VEGF expression and tumor growth and metastasis in vivo. The fact that the growth of human pancreatic cancer cells was significantly suppressed through inhibition of Stat3 activation suggests that blockade of the JAK-STAT signaling pathway is a novel therapeutic approach for pancreatic cancer. Whereas significant progress has been made in defining the molecular mechanisms of pancreatic cancer progression, the specific molecular regulatory pathways affected by these changes have not been fully characterized. Previous studies showed that VEGF is overexpressed in human pancreatic cancer (Brown et al., 1993; Itakura et al., 1997) and constitutively expressed in most pancreatic cancer cell lines (Shi et al., 2001a ,b) . The mechanism of VEGF expression and its regulation in human pancreatic cancer are mostly unknown. However, increasing evidence suggests that in many types of normal and malignant cells, VEGF expression is regulated by a plethora of external factors. Major stimulators of VEGF expression include hypoxia and acidosis, which occur frequently within diverse types of expanding tumors, particularly in regions surrounding necrotic areas (Shweiki et al., 1992) . The major role of hypoxia in the angiogenesis switch has been clearly demonstrated in a mouse model (Bergers et al., 1999) . Hypoxia-mediated VEGF induction involves transactivation of a VEGF promoter by HIF-1 (Levy et al., 1995; Liu et al., 1995) as well as stabilization of VEGF mRNA expression by proteins that bind to sequences located in the 3'-untranslated region of VEGF mRNA (Stein et al., 1995; Damert et al., 1997; Claffey et al., 1998) . Because human pancreatic cancer is generally hypoxic, the VEGF overexpression we observed in human pancreatic Stat 3 and pancreatic cancer angiogenesis D Wei et al cancer tissues was due at least in part to hypoxia and acidosis (Shweiki et al., 1992; Shi et al., 2001b) .
Conversely, in many types of tumors, elevated VEGF production often can be detected in tumor cells located in the extreme periphery of the tumor where there is no apparent hypoxia. This observation is consistent with numerous recent findings indicating that exogenous factors such as hormones, cytokines, and growth factors modulate VEGF expression and thus angiogenesis. These factors include epidermal growth factor (EGF), insulin-like growth factor I (Goad et al., 1996) , fibroblast growth factor (Deroanne et al., 1997) , interleukin-1b (Li et al., 1995) , interleukin-6 (IL-6) (Cohen et al., 1996) , interleukin-8 (Shi et al., 1999) , keratinocyte growth factor (Frank et al., 1995) , plateletderived growth factor (PDGF) (Finkenzeller et al., 1997) , transforming growth factor-b (Pertovaara et al., 1994) , and tumor necrosis factor (Ryuto et al., 1996) . Human pancreatic cancer often exhibits overexpression of these molecules (Korc, 1998) , which coincides with activation of Stat3 and VEGF overexpression as shown in the present study, suggesting a potential link between -4) , and its mutant (lane 5). Reactions of lanes 3 and 4 also contained anti-Stat3 and anti-Stat1 antibodies, respectively. EMSA was performed using whole-cell protein lysates prepared from PANC-1 cells Figure 5 Enforced suppression of constitutive Stat3 activity. FG cells (Lane 1) were transfected with a control vector (lane 2), DNStat3 (lanes 3 and 4) or CA-Stat3 (lanes 5 and 6) expression vectors. (a) VEGF promoter activity was determined using the dual luciferase assay system. Whole-cell protein extracts and cellular mRNA were prepared from the cells. VEGF mRNA expression was determined using Northern blot analysis (b), and VEGF protein secretion was determined using ELISA (c) Ni et al., 2000) , which also induce VEGF expression (Cohen et al., 1996; Wang et al., 1999; Clarke et al., 2001) . Pancreatic cancer cells can also produce leukemia inhibitory factor (LIF), although the function of LIF in tumor development and progression is unclear (Kamohara et al., 1994) . In cardiac myocytes, activation of gp130 by LIF increases VEGF mRNA expression, which is associated with Stat3 activation (Funamoto et al., 2000) , and hypoxic stimulation augments the expression of cardiotrophin-1, a novel cytokine that belongs to the IL-6 cytokine family and activates the gp130-dependent signaling pathway to activate Stat3 (Hishinuma et al., 1999) . Although VEGF expression can be induced dramatically by external factors such as hypoxia, many tumors constitutively express VEGF without any apparent external stimuli. In fact, loss or inactivation of tumor suppressor genes and activation of oncogenes are associated with VEGF overexpression (Kieser et al., 1994; Vanmeir et al., 1994) . For example, loss or inactivation of the wild-type von Hippel-Lindau gene and/or tumor suppressor gene p53 is associated with increased VEGF expression in developing tumors (Kieser et al., 1994; Iliopoulos et al., 1996) . Also, the oncogene v-src increases VEGF expression by inducing HIF-1 expression (Grugel et al., 1995; Rak et al., 1995; Jiang et al., 1997) . Analysis of the VEGF promoter region has revealed several potential transcription factor binding sites, such as HIF-1, AP-1, AP-2, Egr-1, Sp1 (Tischer et al., 1991) , and many others (Ema et al., 1997; Flamme et al., 1997; Akiri et al., 1998; Stein et al., 1998) , suggesting that they may be involved in the regulation of VEGF transcription. Also, we recently defined the cisacting elements and transcription factors involved in constitutive VEGF expression and regulation in human pancreatic adenocarcinoma. We found that human pancreatic adenocarcinoma cells constitutively express VEGF and that the presence of differential levels of constitutive Sp1 expression is strongly correlated with differential levels of constitutive VEGF expression, suggesting that Sp1 plays an important role in tumor angiogenesis and contributes to the aggressive biology of human pancreatic adenocarcinoma. The present study demonstrates that constitutive Stat3 activation is also correlated with constitutive VEGF expression in human pancreatic cancer, suggesting a link between constitutive Stat3 activation and VEGF overexpression.
However, casual evidence of the relation between constitutive and inducible Stat3 activation and VEGF overexpression remains missing. By using a wellestablished constitutive active and dominant-negative Stat3 expression system, we were able to show that blockade of constitutive Stat3 activity significantly downregulated the constitutive expression of VEGF. Our further experiments indicated that Stat3 regulates VEGF expression through direct interaction with the VEGF promoter via a Stat3 response element or elements on the VEGF promoter. Our data also indicated that VEGF can be excessively upregulated via constitutive overactivation of Stat3 by mutation of oncogenes and tumor suppressor genes as well as inducible overactivation of Stat3 by various cytokines, growth factors, and hormones. We are currently investigating the effects of the potential interaction of Stat3 with the transcription factor Sp1 on constitutive VEGF expression as well as the effects of the potential interaction of Stat3 with the transcription factor HIF-1 on inducible VEGF expression stimulated by hypoxia and acidosis.
The fact that Stat3 regulates the key angiogenic factor, VEGF, makes Stat3 a critical transcription factor in tumor development and progression. Previous /mouse) were injected into the pancreas of groups of nude mice (10 mice/cell line). Mice were killed 60 days after tumor injection or when they become moribund. The tumor incident (mice with tumor or metastasis/total mice used), weight (g) and metastates to the liver (median number and range) were determined *Po0.05; **Po0.01
Stat 3 and pancreatic cancer angiogenesis D Wei et al studies demonstrated that Stat3 activation may contribute to tumor growth and metastasis through regulation of several important target genes. It has been shown that Stat3 also contributes to the malignant progression of cancer by preventing apoptosis (Catlett-Falcone et al., 1999) . Abrogation of Stat3 has been shown to decrease the expression of Bcl-xL and an antiapoptotic Bcl-2 family protein (Yu et al., 1995) . Cell cycle regulators such as cyclin D1 have also been found to be transcriptionally upregulated by Stat3 (Bromberg et al., 1999) . Furthermore, expression of the c-myc oncogene, which is involved in cell transformation and apoptosis, is increased by Stat3 activation. Constitutively activated Stat3 protein has been found in various types of tumors, including leukemia and breast, head and neck, and prostate cancer (Watson and Mille, 1995; GouilleuxGruart et al., 1996; Grandis et al., 1998) . In fact, activation of Stat3 has been observed in cells transformed in vitro with by the v-src and v-abl oncogenes (Danial et al., 1995; Yu et al., 1995) , and the constitutively activated Stat3 mutant has been shown to induce cellular transformation and tumor formation in nude mice (Bromberg et al., 1999) . Therefore, Stat3 may enhance tumor growth and metastasis inclusively by affecting the expression of genes related to cell survival and the cell cycle. Our data demonstrate that Stat3 is constitutively activated in human pancreatic cancer cells and directly regulates VEGF expression, providing a novel mechanism in that activation of Stat3 may contribute to human pancreatic cancer progression through regulation of angiogenesis. Therefore, activation of Stat3 contributes to tumor progression through multiple mechanisms. Both tumor-cell proliferation and angiogenesis are essential for cancer metastasis; to that end, activation of Stat3 may promote cancer metastasis. In fact, the DNA binding activity of Stat3 is correlated with malignant ability in human prostate cancer cell lines (Ni et al., 2000) . The contribution of Stat3 activation to pancreatic cancer metastasis is currently under investigation.
In summary, Stat3 is constitutively activated in human pancreatic cancer cells and directly contributes to the overexpression of VEGF. Upstream signaling of constitutive Stat3 activation remains to be defined, however. Targeting of Stat3 signaling may represent a novel approach to controlling the angiogenesis, growth, and metastasis of human pancreatic cancer.
Materials and methods
Animals
Female athymic BALB/c nude mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed in laminar flow cabinets under specific pathogen-free conditions and used when they were 8 weeks old. The animals were maintained in facilities approved by the American Association for the Accreditation of Laboratory Animal Care in accordance with current regulations and standards of the US Department of Agriculture, Department of Health and Human Services, and National Institutes of Health.
Cell lines and culture conditions
The following human pancreatic adenocarcinoma cell lines were used in this study: Bxpc-3, CaPan-2, HPAF-II, HS766T, -1, and SW-1990 , which were purchased from the American Type Culture Collection (Manassas, VA, USA); MDA Panc-3, which was a gift from Dr Paul J Chiao; and COLO 357, which was originally established from a pancreatic adenocarcinoma metastasis by Morgan et al. (1980) , and its fast-growing (FG) and liver metastatic variant (L3.3) in nude mice, which were established by Vezeridis et al. (1990) . All of the cell lines were maintained in plastic flasks as adherent monolayers in minimal essential medium (MEM) supplemented with 15% fetal bovine serum, sodium pyruvate, nonessential amino acids, l-glutamine, and a vitamin solution (Flow Laboratories, Rockville, MD, USA).
PANC
Tumor growth and metastasis
To prepare tumor cells for inoculation, cells in the exponential growth phase were harvested via brief exposure to a 0.25% trypsin/0.02% EDTA solution (wt/vol). Cell viability was determined using trypan blue exclusion, and only single-cell suspensions that were greater than 95% viable were used. To study the kinetics of tumor formation using an ectopic xenograft model, tumor cells (1 Â 10 6 cells/mouse) were injected subcutaneously into nude mice in groups of 10. Caliper measurements of the longest perpendicular tumor diameters were performed once a week to estimate the tumor volume, using the following formula: 4p/3 Â (width/2) 2 Â (length/2), representing the three-dimensional volume of an ellipse. The animals were killed at the end of the study. The tumor weights in all of the groups of mice were determined and compared. To evaluate tumor growth and metastasis, 0.05 ml of the tumor-cell suspensions (1 Â 10 6 cells/mouse) was orthotopically injected into the pancreas of nude mice as described previously (Shi et al., 1999; Wang et al., 2001) . The animals were killed 60 days after tumor-cell implantation or when they had become moribund. Ascites were collected, and pancreatic tumors were harvested and weighed. In addition, each mouse's liver was fixed in Bouin's solution for 24 h to differentiate the neoplastic lesions from the organ parenchyma; metastases on the surface of liver were counted (double-blinded) with the aid of a dissecting microscope as described previously (Shi et al., 1999) .
Northern blot analysis
Tumor cells were cultured in vitro at 75-80% confluency. Cellular mRNA was extracted using the FastTrack mRNA isolation kit (Invitrogen, San Diego, CA, USA). mRNA (2 mg) was separated electrophoretically on a 1% denaturing formaldehyde agarose gel, transferred to a GeneScreen nylon membrane (DuPont, Boston, MA, USA) in 20 Â standard saline citrate, and ultraviolet-crosslinked using a UV-Stratalinker 1800 (Stratagene, La Jolla, CA, USA). Additionally, the VEGF cDNA probe was labeled with [ 32 P]-deoxycytidine triphosphate using a random labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). Equal loading of mRNA samples was monitored by hybridizing the same membrane filter with a human b-actin cDNA probe (Shi et al., 2001a) . To measure VEGF secretion, the VEGF level in the culture supernatants was determined using the Quantikine VEGF ELISA kit (R&D Systems, Minneapolis, MN, USA), which is a quantitative immunometric sandwich enzyme immunoassay. A curve of the absorbance of VEGF vs its concentration in the standard wells was plotted. By comparing the absorbance of the samples with the standard curve, we determined the VEGF concentration in the unknown samples (Shi et al., 2001a) .
Western blot analysis
Whole-cell lysates were prepared from human pancreatic cancer cell lines and tissues. Standard Western blotting was performed using a polyclonal rabbit antibody against activated human ; New England BioLabs, Beverly, MA, USA) and a second antibody (anti-rabbit IgG, a horseradish peroxidase-linked F(ab 0 ) 2 fragment obtained from a donkey; Amersham Life Sciences, Arlington Heights, IL, USA). Equal protein sample loading was monitored by hybridizing the same membrane filter with an anti-b-actin antibody (Ni et al., 2000) . The probe proteins were detected using the Amersham enhanced chemiluminescence system according to the manufacturer's instructions.
EMSA and supershift assay
Whole-cell extracts were prepared from three pairs of normal pancreas and primary pancreatic adenocarcinoma tissues by lysing cells in a high-salt buffer (20 mm HEPES, pH 7.9, 20 mm NaF, 1 mm Na 3 P 2 O 7 , 1mm Na 3 VO 4 , 1mm EDTA, 1 mm EGTA, 1 mm DTT, 0.5 mm phenylmethylsulfonyl fluoride, 420 mm NaCl, 20% glycerol, 1 mg/ml leupeptin, and 1 mg/ml aprotinin) followed by snap-freezing in ethanol/dry ice for 5 min and thawing on ice for 10 min; the freezing and thawing procedures were performed twice. The supernatant was then centrifuged and harvested. Protein concentrations were determined using the Coomassie plus protein assay kit (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's protocol. Whole-cell extracts (20 mg) were incubated in a final volume of 20 ml of 10 mm HEPES, pH 7.9, 80 mm NaCl, 10% glycerol, 1 mm DTT, 1 mm EDTA, 100 mg/ml poly(deoxyinosinic-deoxycytidylic acid) using EMSA with the radiolabeled double-stranded Stat3 consensus-binding motif 5 0 -gatccttctgggaattcctagatc-3 0 (Santa Cruz Biotechnology) or as indicated for 20 min at room temperature. For supershift analyses, the cell extracts were preincubated with specific antibodies against Stat3 and Stat1, respectively (Santa Cruz Biotechnology). The protein-DNA complexes were resolved on a 4.5% nondenaturing polyacrylamide gel containing 2.5% glycerol in 0.25x Tris-borate EDTA at room temperature. The results were autoradiographed. As a confirmation, EMSA also was performed using nuclear protein extract from four more pairs of normal pancreas and primary pancreatic adenocarcinoma tissues as previously described (Ni et al., 2000; Niu et al., 2002) . H7 pancreatic adenocarcinoma cell culture (Wang et al., 2001 ) was stimulated for 6 h with 100 U/ml of IFN-b and the nuclear protein extract was used as control.
Stable Stat3 transfection
FG cells were transfected with constitutively activated Stat3 (CA-Stat3), dominant-negative Stat3 (DN-Stat3), and a vector used alone as a control using LipofectAMINE (Life Technologies, Inc., Rockville, MD, USA). Successful stable transfection was verified using anti-tag antibodies as described previously (Ni et al., 2000) . The dominant-negative Stat3 and vector-alone expression constructs were provided by Dr Koichi Nakajima.
Analysis of VEGF promoter activities
VEGF promoter plasmids containing firefly luciferase reporters (Shi et al., 2001) were cotransfected into tumor cells in triplicate with the internal control pBA-RL using a calcium phosphate method (Mammalian Transfection Kit; Stratagene, La Jolla, CA, USA). The pBA-RL contained a full-length renilla luciferase gene under the control of a human b-actin promoter (provided by Dr Suyun Huang). In some experiments, the reporters were cotransfected with CA-Stat3 or DNStat3 (Ni et al., 2000) . At 6 h after cotransfection, the plates were washed three times with phosphate-buffered saline (PBS) and refed fresh MEM. Both the firefly and renilla luciferase activity were determined 48 h later using the dual luciferase assay kit (Promega, Madison, WI, USA). Specific VEGF promoter activity was calculated as described previously (Shi et al., 2001a) .
Immunohistochemistry
Sections (5 mm thick) of formalin-fixed, paraffin-embedded primary pancreatic adenocarcinoma specimens (10 cases), and normal pancreas tissue specimens (10 cases) were deparaffinized in xylene and rehydrated in graded alcohol. Endogenous peroxidase was blocked using 3% hydrogen peroxide in PBS for 12 min. The specimens were incubated for 20 min at room temperature with a protein-blocking solution consisting of PBS (pH 7.5) containing 5% normal horse serum and 1% normal goat serum and then incubated at 41C in a 1 : 50 dilution of rabbit polyclonal antibody against activated human ; New England BioLabs). The samples were then rinsed and incubated for 1 h at room temperature with peroxidase-conjugated anti-rabbit IgG. Next, the slides were rinsed with PBS and incubated for 5 min with diaminobenzidine (Research Genetics, Huntsville, AL, USA). The sections were washed three times with distilled water, counterstained with Mayer's hematoxylin (Biogenex Laboratories, San Ramon, CA, USA), and washed once each with distilled water and PBS. The slides were mounted using a Universal mount (Research Genetics) and examined using a bright-field microscope. A positive reaction was indicated by a reddish-brown precipitate in the cytoplasm (Shi et al., 1999; Wang et al., 2001) .
The microvessel density of each tumor was analysed via anti-CD31 or CD34 immunostaining. Images were digitized using a Sony 3CD color video camera (Sony, Tokyo, Japan) and personal computer equipped with the Optimas Image Analysis software program (Optimas Corp., Bothell, WA, USA).
Statistical analysis
Each experiment was performed independently at least twice with similar results; one representative experiment is presented. The significance of the in vitro data was determined using Student's t-test (two-tailed), while the significance of the differences between the median values of the in vivo data was determined using the two-tailed Mann-Whitney or KruskalWallis test. P values less than 0.05 were deemed significant.
